DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane

International Journal of Pharmaceutics

Volumn 338, Issue 1-2, 2007, Pages 258-266

  Zhao, Lingyun ^a   Feng, Si Shen ^a   Kocherginsky, Nikolai ^a   Kostetski, Iouri ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticancer drugs; Differential scanning calorimetry (DSC); Electron paramagnetic resonance spectroscopy (EPR); Liposomes; Nanomedicine; Taxol

Indexed keywords

ASCORBIC ACID; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPID; LIPOSOME; NITROXIDE DERIVATIVE; PACLITAXEL; PHOSPHOLIPID;

ARTICLE; CELL MEMBRANE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ELECTRON SPIN RESONANCE; FLUIDIZATION; LIPID BILAYER; LIPID MEMBRANE; MOLECULAR INTERACTION; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCORBIC ACID; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; ELECTRON SPIN RESONANCE SPECTROSCOPY; LIPID BILAYERS; LIPOSOMES; PACLITAXEL;

EID: 34249097200     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.045     Document Type: Article

References (45)

1. Ali S., Minchey S., Janoff A., and Mayhew E. A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes. Biophys. J. 78 (2000) 246-256
2. Ahlin P., Dristl J., Sentjurc M., Strancar J., and Pecar S. Influence of spin probe structure on its distribution in SLN dispersions. Int. J. Pharm. 196 (2000) 241-244
3. Balasubramanian S.V., and Straubinger R.M. Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. Biochemistry 33 (1994) 8941-8949
4. Bartoli H., Boitard M., Fessi H., Beriel H., Devissagnet J.P., Picot F., and Puisien F. In vitro and in vivo antitumoral activity of free and encapsulated taxol. J. Microencapsul. 7 (1990) 191-197
5. Belsito S., Bartucci R., and Sportelli L. Paclitaxel interaction with phospholipid bilayers: high-sensitivity differential scanning calorimetric study. Thermochim. Acta 427 (2005) 175-180
6. Bernsdorff C., Reszka R., and Winter R. Interaction of the anticancer agent Taxol (TM) (paclitaxel) with phospholipid bilayers. J. Biomed. Mater. Res. 46 (1999) 141-149
7. Budai M., Szabo Zs., Szogyi M., and Grof P. Molecular interactions between DPPC and morphine derivatives: a DSC and EPR study. Int. J. Pharm. 250 (2003) 239-250
8. Budai M., Szabo Zs., Zimmer A., Szogyi M., and Grof P. Studies on molecular interactions between nalidixic acid and liposomes. Int. J. Pharm. 279 (2004) 67-79
9. Burt H.M., Zhang X.C., Philip T., Leanne E., and William L.H. Development of copolymers of poly (d.l.-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloid Surf. B: Biointerface 16 (1999) 161-171
10. Coderch L., Fonollosa J., Pera M.D., Estelrich J., Maza D.L., and Parra J.L. Influence of cholesterol on liposome fluidity by EPR relationship with percutaneous absorption. J. Controlled Release 68 (2000) 85-95
11. Dordunoo S.K., Jackson J.K., Arsenault L.A., Oktaba A.M.C., Hunter W.L., and Burt H.M. Taxol encapsulation in poly (ε-caprolactone) microspheres. Cancer Chemother. Pharmacol. 36 (1995) 279-282
12. Dosio F., Brusa P., Crosasso P., Arpicco S., and Cattel L. Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugates. J. Controlled Release 47 (1997) 293-304
13. Eric K.R. Update on the antitumor activity of paclitaxel in clinical trials. Ann. Pharm. 28 (1994) S28
14. Feng S.S., Gong K., and Chew J.Y. Molecular interactions between lipid and an antineoplastic drug paclitaxel (taxol) within the lipid monolayer at the air-water interface. Langmuir 18 (2002) 4061-4070
15. Fetterly G.J., and Straubinger R.M. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharmasci. 5 (2003) 32
16. Gallois L., Fiallo M., and Suillerot A.G. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles: circular dichroism study. BBA 1370 (1998) 31-40
17. Ghannam M.M., Mady M.M., and Khalil W.A. Interaction of type-I collagen with phospholipid monolayer. Biophys. Chem. 80 (1999) 31-40
18. Greenwald R., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vitro effectiveness. J. Med. Chem. 39 (1996) 424-431
19. Joachim K.S., Velasco A., Coats E.A., Cordes H.P., Kunz B., and Wiese M. The Importance of drug-membrane interaction in drug research and development. Quant. Struct. Act. Relat. 11 (1992) 205-210
20. Joachim K.S., Coats E.A., Cordes H.P., and Wiese M. Drug membrae interaction and the importance for drug transport, distrubution, accumulation, efficacy and resistance. Arch. Pharm. 327 (1994) 601-610
21. Kan P., Chen Z.B., Lee C.J., and Chu I.M. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J. Controlled Release 58 (1999) 271-278
22. Kristl J., Volk B., Ahlin P., Gombac K., and Sentjurc M. Interactions of solid lipid nanoparticles with model membranes and leukocytes studies by EPR. Int. J. Pharm. 256 (2003) 133-140
23. Kocherginsky N.M., Syakste N.I., Berkovich M.A., and Devichensky V.M. Study of spin probes with ascorbic acid in solution and on biomembranes. Biofizika 26 (1981) 442-453
24. Kocherginsky, N.M., Swartz, H.M., 1995. Nitroxide spin labels. Reactions in Biology and Chemistry. New York, CRC press.
25. Kunstfeld R., Wickenhauser G., Michaelis U., Teifel M., Umek W., Naujoks K., Wolff K., and Petzelbauer P. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J. Invest. Dermatol. 120 (2003) 476-482
26. Lange A., Marsh D., Wassmer K.H., Meier P., and Kothe G. Electron spin resonance study of phospholipid membranes employing a comprehensive line-shape model. Biochemistry 24 (1985) 4383-4392
27. Marsh D., and Horvath L.I. Structure, dynamic and compostion of the lipid-protein interface: perspectives from spin-labelling. BBA 1376 (1998) 267-296
28. Moser M., Marsh D., Meier P., Wassmer P.K.H., and Kothe G. Chain configuration and flexibility gradient in phospholipid membranes. Comparison between spin-label electron spin resonance and deuteron nuclear magnetic resonance and identification of new conformations. Biophys. J. 55 (1989) 111-123
29. Nagumo A., Sato Y., and Suzuki Y. Electron spin resonance studies of phosphatidylcholime interacted with cholesterol and with hopanoid in liposomal membrane. Chem. Pharm. Bull. 39 (1991) 3071-3074
30. Nussbaum C.F., Eichhorn M.E., Dellian M., Sauer B., Schulze B., Teifel M., Michaelis U., Berghaus A., and Strieth S. Enhanced in vivo platelet adhesion by neovascular targeting therapy of solid tumors using paclitaxel encapsulated in cationic liposomes. J. Vasc. Res. 41 (2004) 449-450
31. Onyuksel H., Ramakrishanan S., Chai H.B., and Pezzuto J.M. A mixed micellar formulation suitable for parenteral administration of taxol. Pharm. Res. 11 (1994) 206-212
32. Perkins R.C., Beth A.H., Wikerson L.S., Serafin W., Dalton L.R., Park C.R., and Park J.H. Enhancement of free radical reduction by elevated concentrations of ascorbic acid in avian dystrophic muscle. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 790-792
33. Prenner E.J., Lewis R.N.A.H., Niaraki M.J., Hodges R.S., and McElhaney R.N. Cholesterol attenuates the interaction of the antimicrobial peptide gramicidin S with phospholipid bilayer membranes. BBA 1510 (2001) 83-92
34. Raimund M., Kubinyi H., and Folkers G. Drug-Membrane Interactions (2002), GmbH, Weinheim, Germany
35. Rodrigues M., Carter P., Wirth C., Mullins S., Lee A., and Blackburn B.K. Synthesisand β-lactamase-mediated activation of cephalosporin-taxol prodrug. Chem. Biol. 2 (1995) 223-227
36. Schmitt-Sody M., Strieth S., Krasnici S., Sauer B., Schulze B., Teifel M., Michaelis U., Naujoks K., and Dellian M. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 9 (2003) 2335-2341
37. Soderlund T., Lehtonen J.Y.A., and Kinnunen P.K.J. Interactions of cyclosporin A with phospholipid membranes: effect of cholesterol. Mol. Pharmcol. 55 (1999) 32-38
38. Streith S., Eichhorn M.E., Sauer B., Schulze B., Teifel M., Michaelis U., and Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer 110 (2004) 117-124
39. Tarr B., Sambandan T.G., and Yalkowsky S.H. A new parenteral emulsion for administration of taxol. Pharm. Res. 4 (1987) 162-165
40. Wenk M.R., Fahr A., Reszka R., and Seelig J. Paclitaxel partitioning into lipid bilayers. J. Pharm. Sci. 85 (1996) 228-231
41. Yeagle P.L. Cholesterol and the cell membrane. BBA 822 (1995) 267-287
42. Zhao L.Y., Feng S.S., and Go M.L. Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J. Pharm. Sci. 93 (2004) 86-97
43. Zhao L.Y., and Feng S.S. Effects of lipid chain length on the molecular interaction between paclitaxel and modelled biomembranes. J. Colloid Interface Sci. 274 (2005) 55-68
44. Zhao L.Y., and Feng S.S. Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J. Colloid Interface Sci. 285 (2005) 326-335
45. Zhao L.Y., and Feng S.S. Effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within the lipid monolayer at the air-water interface. J. Colloid Interface Sci. 300 (2006) 314-326